MedicaidCoverageMedium impact
Technical Bulletin: Expanded April 2026 Administration Window for RSV Prevention in Nevada
Nevada Medicaid·NV · Pediatrics, OB-GYN, Family Medicine·Provider Announcement
Effective date
Apr 2, 2026
We identified it
Jun 21, 2026
Summary
Nevada has extended the administration window for RSV prevention through April 30, 2026, allowing continued billing for infant RSV monoclonal antibodies (nirsevimab and clesrovimab) and maternal RSV vaccination (Abrysvo) during pregnancy beyond the typical March cutoff. This extension applies to Nevada Medicaid and affects billing eligibility for RSV preventive treatments.
Action Required
Through April 30, 2026: Nevada providers should continue billing for RSV monoclonal antibody administration to eligible infants under 8 months and certain high-risk children 8-19 months. Also bill for maternal RSV vaccination (Abrysvo) for pregnant persons at 32-36 weeks gestation during April 2026. Billing team must verify patient eligibility according to CDC/FDA criteria and coordinate with payer teams to ensure claims processing during this extended window.